Olema Pharmaceuticals (OLMA): Price and Financial Metrics
OLMA Price/Volume Stats
| Current price | $10.71 | 52-week high | $17.79 |
| Prev. close | $10.82 | 52-week low | $3.55 |
| Day low | $10.65 | Volume | 513,600 |
| Day high | $11.05 | Avg. volume | 788,430 |
| 50-day MA | $12.72 | Dividend yield | N/A |
| 200-day MA | $12.09 | Market Cap | 598.85M |
OLMA Stock Price Chart Interactive Chart >
Olema Pharmaceuticals (OLMA) Company Bio
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Latest OLMA News From Around the Web
Below are the latest news stories about OLEMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OLMA as an investment opportunity.
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesPalazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile consistent with the FDA-approved labels of ribociclib or palbociclib plus an endocrine therapyOPERA-01 trials-in-progress poster outlines Phase 3 trial design; clinical sites activated and enrolling with first patient dosed in November 2023Olema will host an investor conference call at 8:00 a.m. ET |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to three new employees to purchase an aggregate of 57,500 shares of the Company's common stock, effective as of December 1, 2023. These awards were approved by the Compensation |
Top Stocks for December 2023The top stocks have the performance of well-run companies, a steady performance, and the potential for future growth. In addition, top stocks turn over more shares and thus have plenty of liquidity to reduce your transaction costs. Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity market. |
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET on Dec. 8, 2023 SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical |
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's WhyOlema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication. |
OLMA Price Returns
| 1-mo | -7.27% |
| 3-mo | -5.05% |
| 6-mo | 1.13% |
| 1-year | 167.75% |
| 3-year | -69.11% |
| 5-year | N/A |
| YTD | -23.66% |
| 2023 | 472.65% |
| 2022 | -73.82% |
| 2021 | -80.53% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...